Updates to the AHA’s Cardiovascular Disease Risk Calculator, with Michael Shlipak, MD, MPH

News
Video

Michael Shlipak, MD, MPH, explains updates to the American Heart Association's cardiovascular risk equation, which now incorporates kidney function and damage through albuminuria into its components.

The risk factors for cardiovascular disease, such as diabetes, smoking, dyslipidemia, and high blood pressure, have long been recognized. However, a recent development is the acknowledgment of chronic kidney disease as a significant risk factor for cardiovascular issues. This recognition is reflected in the new cardiovascular risk equation from the American Heart Association, which now incorporates kidney function and damage through albuminuria into its components.

In an interview with HCPLive,Michael Shlipak, MD, MPH, associate chief of medicine for research at the San Francisco VA Medical Center and a professor of medicine at the University of California, San Francisco School of Medicine, discusses his National Kidney Foundation (NKF) 2024 Spring Clinical Meeting presentation on the updated American Heart Association’s cardiovascular disease risk calculator.

While family history is widely acknowledged as a risk factor for cardiovascular disease, modern genetic studies have enabled the development of genetic risk scores. These scores contribute to understanding cardiovascular risk, although they do not account for a significant portion of it. His session highlighted the importance of the new cardiovascular risk equation, particularly in primary care settings, where physicians utilize cardiovascular risk assessment tools to determine appropriate preventive therapies for patients, such as statins or aspirin.

The updated risk equation offers several advantages over its predecessor, including a larger population size and broader diversity in age and ethnicity. Notably, it excludes race and instead utilizes a social deprivation index to capture environmental factors. Additionally, the incorporation of kidney function measures, such as estimated glomerular filtration rate (eGFR) and albuminuria, as well as heart failure as an outcome, enhances its predictive accuracy and relevance, especially for individuals with kidney disease.

Shlipak explains although the new risk calculator represents a significant advancement, there are considerations to address, such as individuals with extreme family history of cardiovascular disease and the need for further validation in different geographic settings. Moreover, he emphasizes the importance of routine kidney testing, particularly urine albumin tests, in primary care settings is crucial for early detection and management of kidney disease and for predicting cardiovascular risk accurately.

Disclosures: Shlipak has participated in advisory boards for Beyer, Boehringer Ingelheim, and AstraZeneca. He receives research funding from Beyer.

Related Videos
What Makes JAK Inhibitors Safe in Dermatology
Potential JAK Inhibitor Combination Regimens in Dermatology
Therapies in Development for Hidradenitis Suppurativa
"Prednisone without Side Effects": The JAK Inhibitor Ceiling in Dermatology
Discussing Changes to Atopic Dermatitis Guidelines, with Robert Sidbury, MD, MPH
Ghada Bourjeily, MD: Research Gaps on Sleep Issues During Pregnancy
John Winkelman, MD, PhD: When to Use Low-Dose Opioids for Restless Legs Syndrome
Bhanu Prakash Kolla, MBBS, MD: Treating Sleep with Psychiatric Illness
How Will Upadacitinib, Povorcitinib Benefit Hidradenitis Suppurativa?
© 2024 MJH Life Sciences

All rights reserved.